MGRX vs. MRAI, ENZ, BRTX, OTRK, SSY, BGLC, ACON, DHAC, ATIP, and VSEE
Should you be buying Mangoceuticals stock or one of its competitors? The main competitors of Mangoceuticals include Marpai (MRAI), Enzo Biochem (ENZ), BioRestorative Therapies (BRTX), Ontrak (OTRK), SunLink Health Systems (SSY), BioNexus Gene Lab (BGLC), Aclarion (ACON), Digital Health Acquisition (DHAC), ATI Physical Therapy (ATIP), and Vsee Health (VSEE). These companies are all part of the "healthcare" industry.
Mangoceuticals vs.
Mangoceuticals (NASDAQ:MGRX) and Marpai (NASDAQ:MRAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, media sentiment, dividends, analyst recommendations, earnings, risk, profitability and valuation.
Marpai has a net margin of -85.70% compared to Mangoceuticals' net margin of -1,237.00%. Marpai's return on equity of 0.00% beat Mangoceuticals' return on equity.
56.7% of Mangoceuticals shares are held by institutional investors. Comparatively, 49.8% of Marpai shares are held by institutional investors. 16.0% of Mangoceuticals shares are held by insiders. Comparatively, 61.3% of Marpai shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Mangoceuticals has higher earnings, but lower revenue than Marpai. Marpai is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Mangoceuticals and Mangoceuticals both had 1 articles in the media. Marpai's average media sentiment score of 0.68 beat Mangoceuticals' score of -0.95 indicating that Marpai is being referred to more favorably in the news media.
Mangoceuticals has a beta of 2.45, indicating that its share price is 145% more volatile than the S&P 500. Comparatively, Marpai has a beta of 4.74, indicating that its share price is 374% more volatile than the S&P 500.
Marpai received 2 more outperform votes than Mangoceuticals when rated by MarketBeat users.
Summary
Marpai beats Mangoceuticals on 9 of the 13 factors compared between the two stocks.
Get Mangoceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for MGRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mangoceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:MGRX) was last updated on 5/23/2025 by MarketBeat.com Staff
Buy MGRX Stock Free MGRX Stock Alerts